Last reviewed · How we verify
Recombinant-methionyl human stem cell factor — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Recombinant-methionyl human stem cell factor (Recombinant-methionyl human stem cell factor) — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Recombinant-methionyl human stem cell factor TARGET | Recombinant-methionyl human stem cell factor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Recombinant-methionyl human stem cell factor CI watch — RSS
- Recombinant-methionyl human stem cell factor CI watch — Atom
- Recombinant-methionyl human stem cell factor CI watch — JSON
- Recombinant-methionyl human stem cell factor alone — RSS
Cite this brief
Drug Landscape (2026). Recombinant-methionyl human stem cell factor — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-methionyl-human-stem-cell-factor. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing